

#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LÜTTICKEN ET AL.

Serial No.: 09/084,837

Group Art Unit: 1643

Filed: May 26, 1998

Examiner: M. Mosher

For: RECOMBINANT BIRNAVIRUS VACCINE

INFORMATION DISCLOSURE STATEMENT AND TRANSMITTAL
OF FEE PURSUANT TO 37 CFR 1.97 (c)

Assistant Commissioner of Patents
Washington, D.C. 20231

February 8, 1999

Sir:

The attention of the Patent and Trademark Office is hereby directed to the document listed on the attached Form PTO-1449.

A copy of the document is attached.

This Information Disclosure Statement is being submitted after issuance of a first official action on the merits and expiration of the three month period following filing of the above-captioned application, but prior to issuance of either a final official action or a Notice of Allowance. The \$200 fee set forth in 37 CFR Section 1.17 (p) may be charged to Deposit Account No. 02-2334.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on 2/8/99
Date Of Deposit


-1-

Mary E. Gornley
Registration No. 34,409

Mary E. Gornley 2/8/99
Signature Date

The Commissioner is hereby authorized to charge any additional fee (or credit any overpayment) associated with this statement to our Deposit Account No. 02-2334.

Respectfully submitted,


Mary E. Gormley
Attorney for Applicants
Registration No. 34,409

Attorney Docket No. I/97269 US

AKZO NOBEL PATENT DEPT.
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850
Tel: (301) 948-7400
Fax: (301) 948-9751

MEG:jlc

29luttic.ids